麻豆视频

Market Trends and Insights

Rising Type-2 Diabetes Burden

Type 2 diabetes provides a broad patient base for the South America alpha-glucosidase inhibitors market. The International Diabetes Federation estimated that 35.4 million adults in South and Central America lived with diabetes in 2024, generating USD 81 billion in diabetes-related healthcare expenditure.^{[1]International Diabetes Federation, “South and Central America Region,” IDF Diabetes Atlas, diabetesatlas.org} It also reported that 30.4% of people with diabetes, or more than 10.7 million individuals, were undiagnosed. Colombia had 3.0 million adults with diabetes in 2024, with 16.2% of cases undiagnosed. The regional diabetes population is projected to reach 52 million by 2050, supporting demand for postprandial glucose-control therapies.^{[2]International Diabetes Federation, “Diabetes Data in Colombia,” IDF Diabetes Atlas, diabetesatlas.org}

Oral Therapy Access and Lower-Cost Generic Treatment

Oral medications remain important in Type 2 diabetes management, as injectable treatments can be unaffordable for patients without private coverage. Clinical guidelines across Latin America position established oral therapies as core treatments, while newer drugs primarily target patients with cardiovascular or kidney risks. Alpha-glucosidase inhibitors retain a role when patients cannot tolerate metformin or require postprandial glucose control. Generic acarbose and miglitol improve affordability, while Brazil’s pricing framework requires generics to be priced at least 35% below reference products. However, increasing generic competition may pressure unit prices.

Expansion of Private Diabetes-Care Networks

Private diabetes care networks in Brazil, Argentina, and Colombia expand prescribing channels for oral antidiabetic medications. Specialist practices in Buenos Aires, Bogotá, and S?o Paulo manage chronic disease patients requiring multiple therapies, supporting alpha-glucosidase inhibitors as add-on treatments for postprandial glucose control. Private retail pharmacies remain important where public procurement programs do not routinely supply these products. Brazil’s pharmacy networks and digital pharmacy services support prescription refill access outside the public healthcare system. Consequently, the market remains linked to household purchasing power, private reimbursement, and retail pharmacy coverage.

Public Formulary Gaps and Established Prescribing Patterns

Limited availability in selected public formularies affects patient access to alpha-glucosidase inhibitors. Acarbose and miglitol are not standard medications for Type 2 diabetes management under Brazil’s public essential medicines framework, shifting many prescriptions to private retail outlets. This increases the importance of pharmacy availability and out-of-pocket affordability while reducing exposure to public tender cycles. The established use of acarbose supports continued prescribing among physicians familiar with the reference product and its generic versions. This retail-led distribution model supports demand in areas with active private care while limiting access in regions dependent on public reimbursement.

Competition from Newer Diabetes Therapies

Competition from metformin, SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors is a key restraint on the South America alpha-glucosidase inhibitors market. In May 2026, Brazil’s National Health Surveillance Agency registered Eurofarma’s first generic fixed-dose combination of dapagliflozin and metformin hydrochloride, expanding access to lower-cost oral treatment options for type 2 diabetes. Clinical guidelines prioritize SGLT2 inhibitors for patients with cardiovascular disease, heart failure, or diabetic kidney disease, reducing the target patient pool for alpha-glucosidase inhibitors. Competition is strongest in private insurance formularies and urban specialist settings, although the class remains relevant where newer therapies are unsuitable, unavailable, or unaffordable.

Gastrointestinal Tolerability and Uneven Access

Alpha-glucosidase inhibitors can cause flatulence, bloating, and diarrhea due to carbohydrate fermentation in the colon, which may lead to treatment discontinuation and lower refill volumes. These effects create challenges where physician counseling and treatment monitoring are limited. Miglitol’s absorption profile partly mitigates these concerns and supports its faster growth within the drug class. Fragmented retail and tender channels in Peru and smaller countries, along with limited public reimbursement, uneven pharmacy coverage, and inadequate adherence support, constrain market access and supply consistency.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

South America Alpha Glucosidase Inhibitors Market Segment Analysis

Acarbose held 59.80% of the South America alpha-glucosidase inhibitors market in 2025. Its leadership reflects Bayer’s Glucobay presence as a reference product across South American regulatory systems and the availability of generic alternatives. Familiarity among endocrinologists and general practitioners, particularly in Brazil’s interior states and Argentina’s provincial markets, continues to support prescribing. Generic supply from Brazilian and Indian manufacturers improves access for price-sensitive patients, while voglibose and combination products maintain limited roles.

Miglitol is forecast to grow at a 6.89% CAGR from 2026 to 2031, making it the fastest-growing drug type. Its absorption profile supports selected patients with early-stage type 2 diabetes and high post-meal glucose levels, particularly when renal conditions limit metformin use. Prescribers in Brazil and Colombia are becoming more familiar with its use, although careful patient selection remains necessary because glucagon cannot be used to manage associated hypoglycemia. Local generic availability can further support segment growth.

Type 2 diabetes accounted for 53.56% of the South American alpha-glucosidase inhibitors market in 2025 and is forecast to grow at a 6.22% CAGR through 2031. The regional adult diabetes population is projected to reach 52 million by 2050, up from 35.4 million in 2024. Alpha-glucosidase inhibitors are used when post-meal hyperglycemia is prominent, metformin is not tolerated, or avoiding hypoglycemia is important. The class remains a second-line option when newer medicines are contraindicated or unaffordable.

Type 1 diabetes represents a smaller and more stable indication in the South American alpha-glucosidase inhibitors market. Specialist-managed care may use these drugs off-label to reduce post-meal glucose fluctuations in patients on intensive insulin regimens. However, formal guidance does not strongly support routine use, while continuous glucose monitoring and insulin adjustment remain preferred approaches. Gastrointestinal side effects and strict dietary regimens further limit repeat prescriptions.

Retail pharmacies captured 59.76% of the distribution value in 2025, making them the leading channel in the South American alpha-glucosidase inhibitors market. Their position reflects the limited availability of acarbose and miglitol through public procurement systems across the region. In Brazil, private pharmacies fill prescriptions not covered by the public essential medicines framework. Household income and private insurance reimbursement remain key factors influencing channel performance.

Online pharmacies are forecast to grow at a 5.72% CAGR from 2026 to 2031. Digital refill systems support treatment continuity for patients using chronic oral medicines, while expanding e-commerce adoption in Brazil, Argentina, and Colombia improves access beyond traditional pharmacy locations. Although GLP-1 products have driven initial online diabetes sales, the digital infrastructure also supports oral therapies. The channel is becoming increasingly relevant for scheduled refills and patient support.

Geography Analysis

Brazil and Colombia Alpha Glucosidase Inhibitors Market

Brazil held 45.87% of the regional market value in 2025, supported by its large diabetes population, pharmaceutical manufacturing base, and extensive retail pharmacy network. An estimated 16.6 million people in Brazil lived with diabetes in 2024, representing a national prevalence of 10.6%. The Northeast recorded diabetes prevalence above the national average but had less developed distribution infrastructure than the Southeast, creating opportunities for lower-cost generics through retail and online channels. Colombia contributes through public hospital procurement and private retail distribution, with 3.0 million adults living with diabetes in 2024, according to the International Diabetes Federation.

Argentina Alpha Glucosidase Inhibitors Market

Argentina is forecast to grow at a 5.45% CAGR through 2031, the highest rate among the geographic markets. The country had a diabetes population of 4.3 million and a national prevalence of 14%, among the highest in the region. Its pharmaceutical base in Buenos Aires Province supports generic oral antidiabetic production. 

Broader South American Markets

Chile represents a mid-tier opportunity because branded alpha-glucosidase inhibitors retain a stronger presence in private insurance channels. However, SGLT2 inhibitors are increasingly displacing the class in some private formularies. Peru and the Rest of South America, including Ecuador, Bolivia, Paraguay, Uruguay, and Venezuela, rely heavily on imported medicines and public procurement systems that do not prioritize alpha-glucosidase inhibitors. Peru’s private healthcare market in Lima and Arequipa supports modest branded acarbose demand. At the same time, Bolivia, Ecuador, and Paraguay offer early-stage opportunities as screening, primary care access, formulary inclusion, and pharmaceutical distribution improve.